Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb 3;13(2):153.
doi: 10.3390/antibiotics13020153.

Clinical Effectiveness of Continuous Infusion Flucloxacillin in the Outpatient Parenteral Antimicrobial Therapy (OPAT) Setting in a UK Hospital: A Service Evaluation

Annette Margaret Clarkson  1 , Susan Snape  2
Affiliations

Clinical Effectiveness of Continuous Infusion Flucloxacillin in the Outpatient Parenteral Antimicrobial Therapy (OPAT) Setting in a UK Hospital: A Service Evaluation

Annette Margaret Clarkson et al. Antibiotics (Basel). .

Abstract

The availability of stability data for the use of continuous intravenous flucloxacillin in an elastomeric device has enabled the treatment of serious Methicillin Sensitive Staphylococcus aureus (MSSA) in the outpatient parenteral antimicrobial therapy (OPAT) setting. This service review aimed to evaluate current standard of care to establish the clinical effectiveness and complication rates associated with its use since its introduction at our institution. A retrospective review of clinical outcomes and adverse events/complications, was undertaken for all patients who received continuous infusion flucloxacillin for complicated MSSA infection between January 2019 and July 2022 via our OPAT service. Thirty-nine patients were included. An OPAT treatment outcome of 'Treatment aim attained uncomplicated' was achieved in 29/39 (74%) patients. Two patients had an OPAT treatment outcome of treatment aim not attained, both of which required unexpected hospital re-admission. An adverse event/complication occurred in 8 patients. There were two relapses in the 12-month follow-up period. Our review supports the assertion that continuous infusion flucloxacillin is clinically effective and well tolerated for the treatment of complicated MSSA infection in the OPAT setting.

Keywords: MSSA; OPAT; Staphylococcus aureus bacteraemia; continuous infusion; elastomeric device; flucloxacillin.

PubMed Disclaimer

Conflict of interest statement

Authors declare no conflicts of interest.

References

    1. Turnidge J.D. The pharmacodynamics of β-Lactams. Clin. Infect. Dis. 1998;27:10–22. doi: 10.1086/514622. - DOI - PubMed
    1. Yetmar Z., Khodadadi R.B., Go J.R., Chesdachai S., Abu Saleh O.M. Post treatment outcome of ceftriaxone versus antistaphylococcal penicillins or cefazolin for definitive therapy of methicillin susceptible Staphylococcus aureus bacteraemia. Eur. J. Clin. Microbiol. Infect. Dis. 2023;42:423–430. doi: 10.1007/s10096-023-04575-z. - DOI - PubMed
    1. Buis D.T., van der Vaart T.W., Prins J.M., van der Meer J.T., Bonten M.J., Sieswerda E., van Werkhoven C.H., Sigaloff K.C., Herpers B.L. Comparative effectiveness of beta-lactams for empirical treatment of methicillin-susceptible Staphylococcus aureus bacteraemia: A prospective cohort study. J. Antimicrob. Chemother. 2023;78:1175–1181. doi: 10.1093/jac/dkad057. - DOI - PMC - PubMed
    1. Chapman A.L.N., Patel S., Horner C., Green H., Guleri A., Hedderwick S., Snape S., Statham J., Wilson E., Gilchrist M., et al. Updated good practice recommendations for outpatient parenteral antimicrobial therapy (OPAT) in adults and children in the UK. JAC Antimicrob. Resist. 2019;1:dlz026. doi: 10.1093/jacamr/dlz026. - DOI - PMC - PubMed
    1. Allwood M.C., Stonkute D., Wallace A., Wilkinson A.S., Hills T., Jamieson C. Assessment of stability of citrate buffered flucloxacillin for injection when stored in two commercially available ambulatory elastomeric devices: INfusor LV (Baxter) and Accufuser (Woo Young medical): A study compliant with the NHS yellow cover document (YCD) requirements. Eur. J. Hosp. Pharm. 2020;27:90–94. doi: 10.1136/ejhpharm-2018-001515. - DOI - PMC - PubMed

LinkOut - more resources